- PLN40.25m
- PLN55.95m
- PLN60.90m
Brief: Biomaxima Management Recommends 2021 Dividend At 0.45 Zloty/Shr
Brief: BioMaxima Signs 3.2 Mln Zlotys Deal With Polish Pharmaceutical Company
Brief: Biomaxima Feb Sales Revenue At 38.5 Mln Zlotys
Brief: Biomaxima Jan Sales Revenue At 43.7 Mln Zlotys
Poland - Factors to Watch Feb 1
Poland - Factors to Watch Jan 31
Brief: Biomaxima Gets 94.8 Mln Zloty Order For SARS-CoV-2 Tests
Brief: Biomaxima Says Prelim Q4 Revenue At 23.2 Mln Zlotys
Brief: Biomaxima Signs 8.9 Mln Zloty Deal For Rapid Antigene SARS-CoV-2 Tests
Brief: Biomaxima Prelim Q3 Standalone Sales Revenue At 14.4 Mln Zlotys, Up 101.58% Y/Y
Brief: Biomaxima Says Files To KNF For Listing On Regulated Market
Brief: BioMaxima Q1 Net Result Turns To Profit Of 6.4 Mln Zlotys
Brief: Biomaxima Prelim Q1 Standalone Sales Revenue At 26.4 Mln Zlotys
Polish BioMaxima eyes takeovers after its value surged on pandemic
Brief: Biomaxima Signs Deal With Germany-Based Distributor On Products Related To Sars-Cov-2 Diagnostics
Brief: Biomaxima Files For Registration Of SARS-CoV-2 Antibody Rapid Test
Brief: BioMaxima Management To Recommend 2020 Dividend Of 0.25 Zloty/Shr
Brief: Biomaxima Gets Order For Sars-Cov-2 Tests From Contractor In Spain
Brief: BioMaxima Q4 Net Profit Up At 3.4 Mln Zlotys